COMMUNIQUÉ DE PRESSE publié le 16/04/2024 à 13:00, il y a 5 mois 3 jours CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines CureVac and MD Anderson announce strategic collaboration to develop mRNA-based cancer vaccines, leveraging respective expertise to address unmet medical needs in hematological and solid tumors Clinical Research Collaboration CureVac MD Anderson MRNA-based Cancer Vaccines
BRÈVE publiée le 04/04/2024 à 13:05, il y a 5 mois 15 jours CureVac annonce des résultats positifs de phase 2 pour son vaccin contre la grippe en collaboration avec GSK GSK Technologie ARNm CureVac Vaccin Contre La Grippe Essai De Phase 2
BRÈVE publiée le 04/04/2024 à 13:05, il y a 5 mois 15 jours CureVac Reports Positive Phase 2 Results for Influenza Vaccine in Collaboration with GSK GSK MRNA Technology CureVac Influenza Vaccine Phase 2 Trial
COMMUNIQUÉ DE PRESSE publié le 04/04/2024 à 13:00, il y a 5 mois 15 jours CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK CureVac announces positive Phase 2 interim results for seasonal influenza vaccine in collaboration with GSK, showing strong antibody titers and safety profile GSK CureVac Phase 2 Seasonal Influenza Vaccine MRNA
COMMUNIQUÉ DE PRESSE publié le 01/11/2023 à 13:00, il y a 10 mois 18 jours CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
COMMUNIQUÉ DE PRESSE publié le 28/09/2023 à 13:00, il y a 11 mois 21 jours CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany
COMMUNIQUÉ DE PRESSE publié le 12/09/2023 à 13:15, il y a 1 année CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
COMMUNIQUÉ DE PRESSE publié le 12/09/2023 à 13:00, il y a 1 année CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
COMMUNIQUÉ DE PRESSE publié le 17/08/2023 à 13:00, il y a 1 année 1 mois CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
COMMUNIQUÉ DE PRESSE publié le 01/08/2023 à 13:00, il y a 1 année 1 mois CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
Publié le 19/09/2024 à 17:45, il y a 5 heures 48 minutes Gimv draagt helft van participatie in Infravest over aan WorxInvest (communicatie in toepassing van artikel 7:97 WVV)
Publié le 19/09/2024 à 17:45, il y a 5 heures 48 minutes Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Publié le 19/09/2024 à 17:45, il y a 5 heures 48 minutes Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Publié le 19/09/2024 à 23:15, il y a 18 minutes Cypher Metaverse Inc. Announces Second Closing of Financing
Publié le 19/09/2024 à 23:00, il y a 33 minutes WestJet Partners with FLYHT and NOAA to Improve Weather Forecasting in North America
Publié le 19/09/2024 à 20:15, il y a 3 heures 18 minutes Living Security Named a Leader in Human Risk Management, Closely Watched Tech Industry Report
Publié le 19/09/2024 à 21:09, il y a 2 heures 23 minutes EQS-Adhoc: Mercedes-Benz Group AG adjusts full-year guidance for the year 2024 based on current market outlook
Publié le 19/09/2024 à 18:44, il y a 4 heures 48 minutes Fuller, Smith & Turner PLC: Transaction in own shares
Publié le 19/09/2024 à 18:03, il y a 5 heures 30 minutes Funding Circle Plc: POS-Transaction in Own Shares
Publié le 19/09/2024 à 17:52, il y a 5 heures 40 minutes PILOT 28 : FIGEAC AÉRO remporte 3 nouveaux contrats sur l'A320 pour 65 millions d'euros
Publié le 19/09/2024 à 17:52, il y a 5 heures 40 minutes PILOT 28: FIGEAC AÉRO secures 3 new wins on the A320 airframe for 65 million euros